Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Jan-Willem B. de Groot"'
Autor:
Olivier J. van Not, Alfons J.M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Jesper van Breeschoten, Franchette W.P.J. van den Berkmortel, Jan-Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Manja Bloem, Melissa M. De Meza, Djura Piersma, Rozemarijn S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk
Publikováno v:
EClinicalMedicine, Vol 69, Iss , Pp 102485- (2024)
Summary: Background: The prognosis of advanced melanoma patients has significantly improved over the years. We aimed to evaluate the survival per year of diagnosis. Methods: All systemically treated patients diagnosed with advanced melanoma from 2013
Externí odkaz:
https://doaj.org/article/09267a9e520444ec9384e855653228ee
Autor:
Birgit S. Geurts, Thomas W. Battaglia, J. Maxime van Berge Henegouwen, Laurien J. Zeverijn, Gijs F. de Wit, Louisa R. Hoes, Hanneke van der Wijngaart, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Frans L. Opdam, Maja J. A. de Jonge, Geert A. Cirkel, Mariette Labots, Ann Hoeben, Emile D. Kerver, Adriaan D. Bins, Frans G.L. Erdkamp, Johan M. van Rooijen, Danny Houtsma, Mathijs P. Hendriks, Jan-Willem B. de Groot, Henk M. W. Verheul, Hans Gelderblom, Emile E. Voest
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background In this study we aimed to evaluate the efficacy and safety of the PD-L1 inhibitor durvalumab across various mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumours in the Drug Rediscovery Protocol (DRUP
Externí odkaz:
https://doaj.org/article/0e6af27c660548eab8d0d86d81fe251d
Autor:
Esther N. Pijnappel, Melinda Schuurman, Anna D. Wagner, Judith de Vos-Geelen, Lydia G. M. van der Geest, Jan-Willem B. de Groot, Bas Groot Koerkamp, Ignace H. J. T. de Hingh, Marjolein Y. V. Homs, Geert-Jan Creemers, Geert A. Cirkel, Hjalmar C. van Santvoort, Olivier R. Busch, Marc G. Besselink, Casper H.J. van Eijck, Johanna W. Wilmink, Hanneke W. M. van Laarhoven
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundBiological sex, gender and age have an impact on the incidence and outcome in patients with metastatic pancreatic cancer. The aim of this study is to investigate whether biological sex, gender and age are associated with treatment allocatio
Externí odkaz:
https://doaj.org/article/4f79caf484fb429aad6b52f77ca218c8
Autor:
Nienke A. de Glas, Esther Bastiaannet, Frederiek van den Bos, Simon P. Mooijaart, Astrid A. M. van der Veldt, Karlijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan-Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Hilde Jalving, Djura Piersma, Rozemarijn S. van Rijn, Albert J. ten Tije, Gerard Vreugdenhil, Michel W. J. M. Wouters, Johanneke E. A. Portielje, Ellen W. Kapiteijn
Publikováno v:
Cancers, Vol 13, Iss 11, p 2826 (2021)
Background: Previous trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included. The aim of this study was to describe the treatment patterns and
Externí odkaz:
https://doaj.org/article/f8224d2ec13748e9a705501c93b5d001
Autor:
Daan Jan Willem Rauwerdink, Olivier van Not, Melissa de Meza, Remco van Doorn, Jos van der Hage, A. J. M. van den Eertwegh, John B. Haanen, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christiaan U. Blank, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, A. M. Stevense-den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Karijn P. M. Suijkerbuijk, Ellen Kapiteijn
Publikováno v:
Cancers, Vol 16, Iss 15, p 2656 (2024)
Introduction: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant and advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups. Methods: This m
Externí odkaz:
https://doaj.org/article/02c43e3aab1348c3b7328efdfe95b1b5
Autor:
Melissa M. de Meza, Willeke A. M. Blokx, Han J. Bonenkamp, Cristian U. Blank, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Marye J. Boers‐Sonderen, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen W. Kapiteijn, Olivier J. van Not, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense‐Den Boer, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Alfons J. M. van den Eertwegh, Karijn P. M. Suijkerbuijk, Michel W. J. M. Wouters
Publikováno v:
International Journal of Cancer, 153, 2, pp. 389-398
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
de Meza, M M, Blokx, W A M, Bonenkamp, H J, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, Boers-Sonderen, M J, de Groot, J W B, Haanen, J B, Hospers, G A P, Kapiteijn, E W, van Not, O J, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, van den Eertwegh, A J M, Suijkerbuijk, K P M & Wouters, M W J M 2023, ' Adjuvant treatment of in-transit melanoma : Narrowing the knowledge gap left by clinical trials ', International Journal of Cancer, vol. 153, no. 2, pp. 389-398 . https://doi.org/10.1002/ijc.34485
International Journal of Cancer, 153(2), 389-398. Wiley-Liss Inc.
International Journal of Cancer, 153, 389-398
International Journal of Cancer. Wiley
International Journal of Cancer, 153, 389-398. Wiley
Contains fulltext : 292870.pdf (Publisher’s version ) (Open Access) Few clinical trials address efficacy of adjuvant systemic treatment in patients with in-transit melanoma (ITM). This study describes adjuvant systemic therapy of ITM patients beyon
Autor:
Isabella A. J. van Duin, Sjoerd G. Elias, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, Willeke A. M. Blokx, Paul J. van Diest, Tim Leiner, Joost J. C. Verhoeff, Rik J. Verheijden, Olivier J. van Not, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, John B. A. G. Haanen, Geke A. P. Hospers, Anna M. Kamphuis, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michel W. J. M. Wouters, Marion A. M. Stevense‐den Boer, Marye J. Boers‐Sonderen, Ellen Kapiteijn, Karijn P. M. Suijkerbuijk
Publikováno v:
van Duin, I A J, Elias, S G, van den Eertwegh, A J M, de Groot, J W B, Blokx, W A M, van Diest, P J, Leiner, T, Verhoeff, J J C, Verheijden, R J, van Not, O J, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Haanen, J B A G, Hospers, G A P, Kamphuis, A M, Piersma, D, van Rijn, R S, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Stevense-den Boer, M A M, Boers-Sonderen, M J, Kapiteijn, E & Suijkerbuijk, K P M 2023, ' Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma ', International Journal of Cancer, vol. 152, no. 12, pp. 2493-2502 . https://doi.org/10.1002/ijc.34479
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
International Journal of Cancer, 152(12), 2493-2502. Wiley
International Journal of Cancer, 152(12), 2493-2502. Wiley-Liss Inc.
Since the introduction of BRAF(/MEK) inhibition and immune checkpoint inhibition (ICI), the prognosis of advanced melanoma has greatly improved. Melanoma is known for its remarkably long time to first distant recurrence (TFDR), which can be decades i
Autor:
Eline G. M. Steenhuis, Ivonne J. H. Schoenaker, Jan Willem B. De Groot, Jos A. Stigt, Onne Reerink, Wouter H. De Vos tot Nederveen Cappel, Henderik L. Van Westreenen, Richard M. Brohet
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 13, p 3828 (2022)
Purpose: Worldwide, colorectal carcinoma (CRC) has a high incidence and a substantial cancer-related mortality. The recurrence risk is 30–50% and lung metastases are common. Treatment of lung metastases with stereotactic ablative radiotherapy (SABR
Externí odkaz:
https://doaj.org/article/58627bfafdb6482eb95479ad0e30d83c
Autor:
Jesper van Breeschoten, Alfons J.M. van den Eertwegh, Doranne L. Hilarius, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jan Willem B. de Groot, Geke A.P. Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn S. van Rijn, Marion A. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Marye J. Boers-Sonderen, Damjan Manevski, Karijn P.M. Suijkerbuijk, Michel W.J.M. Wouters, Liesbeth C. de Wreede
Publikováno v:
European Journal of Cancer, 182, pp. 132-143
European Journal of Cancer, 182, 132-143. ELSEVIER SCI LTD
European Journal of Cancer, 182, 132-143. Pergamon
van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Manevski, D, Suijkerbuijk, K P M, Wouters, M W J M & de Wreede, L C 2023, ' Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry ', European Journal of Cancer, vol. 182, pp. 132-143 . https://doi.org/10.1016/j.ejca.2023.01.006
European Journal of Cancer, 182, 132-143
European Journal of Cancer, 182, 132-143. Elsevier Ltd.
European Journal of Cancer, 182, 132-143. ELSEVIER SCI LTD
European Journal of Cancer, 182, 132-143. Pergamon
van Breeschoten, J, van den Eertwegh, A J M, Hilarius, D L, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A, van der Veldt, A A M, Vreugdenhil, G, Boers-Sonderen, M J, Manevski, D, Suijkerbuijk, K P M, Wouters, M W J M & de Wreede, L C 2023, ' Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry ', European Journal of Cancer, vol. 182, pp. 132-143 . https://doi.org/10.1016/j.ejca.2023.01.006
European Journal of Cancer, 182, 132-143
European Journal of Cancer, 182, 132-143. Elsevier Ltd.
Introduction: When analysing patient survival, one is often interested in cause of death. Little is known about the presence of population mortality in advanced melanoma pa-tients. The aim of this study was to assess population mortality after differ
Autor:
Henderik L van Westreenen, Vincent M Meyer, I. J. H. Schoenaker, Richtje R Meuzelaar, Geerard L. Beets, Jan-Willem B de Groot, Wouter H. de Vos tot Nederveen Cappel, O. Reerink
Publikováno v:
Diseases of the Colon & Rectum, 66(5), 671-680. LIPPINCOTT WILLIAMS & WILKINS
BACKGROUND: A watch & wait strategy for patients with rectal cancer with a clinical complete response after neoadjuvant chemoradiotherapy is a valuable alternative for rectal resection. However, there are patients who will have residual tumor or regr